Integrated Filing — IndAS



General information about company

Scrip Code 532612
NSE Symbol INDOCO
MSEI Symbol NOTLISTED
ISIN INE873D01024
Name of company INDOCO REMEDIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 28-07-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 15-07-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Single segment
Description of single segment PHARMACEUTICALS
Start date and time of board meeting 28-07-2026   10:45:00
End date and time of board meeting 28-07-2026   11:45:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 46,750.00 46,750.00
Other income 218.00 218.00
Total income 46,968.00 46,968.00
2 Expenses
(a) Cost of materials consumed 10,458.00 10,458.00
(b) Purchases of stock-in-trade 3,989.00 3,989.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 1,358.00 1,358.00
(d) Employee benefit expense 10,141.00 10,141.00
(e) Finance costs 2,829.00 2,829.00
(f) Depreciation, depletion and amortisation expense 3,453.00 3,453.00
(f) Other Expenses
1 RESEARCH & DEVELOPMENT EXPENSES 1,854.00 1,854.00
2 OTHER EXPENSES 14,848.00 14,848.00
Total other expenses 16,702.00 16,702.00
Total expenses 48,930.00 48,930.00
3 Total profit before exceptional items and tax (1,962.00) (1,962.00)
4 Exceptional items 9,734.00 9,734.00
5 Total profit before tax 7,772.00 7,772.00
6 Tax expense
7 Current tax 1,059.00 1,059.00
8 Deferred tax 169.00 169.00
9 Total tax expenses 1,228.00 1,228.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 6,544.00 6,544.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 6,544.00 6,544.00
17 Other comprehensive income net of taxes 68.00 68.00
18 Total Comprehensive Income for the period 6,612.00 6,612.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 6,499.00 6,499.00
Total profit or loss, attributable to non-controlling interests 45.00 45.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 6,567.00 6,567.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 45.00 45.00
21 Details of equity share capital
Paid-up equity share capital 1,846.00 1,846.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 7.09 7.09
Diluted earnings (loss) per share from continuing operations 7.09 7.09
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 7.09 7.09
Diluted earnings (loss) per share from continuing and discontinued operations 7.09 7.09
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The unaudited Consolidated Results for the Quarter ended 30th June, 2026, have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 28th July, 2026. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Consolidated Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: (Rs. in Lakhs) Net Sales Qtr ended Qtr ended Qtr ended Year ended & Income 30-06-2026 31-03-2026 30-06-2025 31-03-2026 from Operations (Unaudited) (Audited) (Unaudited) (Audited) India 31,177 24,714 27,783 1,12,412 Outside India 15,445 20,876 15,303 66,882 --------------------------------------------------------------------------------------------------------------------------- Total : 46,622 45,590 43,086 1,79,294============================================================== 5. The Consolidated Financial Results includes the results of the following companies. ----------------------------------------------------------------------------------------------------------------------------- Name of the Company % of shareholding Consolidated as ------------------------------------------------------------------------------------------------------------------------------ XTEND INDUSTRIAL DESIGNERS 100.00 SUBSIDIARY & ENGINEERS PVT LTD INDOCO REMEDIES CZECH SRO 100.00 SUBSIDIARY INDOCO REMEDIES UK LTD 100.00 SUBSIDIARY WARREN REMEDIES PVT LTD 100.00 SUBSIDIARY FPP HOLDING COMPANY, LLC 85.00 SUBSIDIARY -------------------------------------------------------------------------------------------------------------------------- 6. Figures for the quarter ended 31.3.2026 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2025 (limited reviewed). 7. (*) The Company completed the slump sale of its Ophthalmic Business Division to Sunways (India) Private Limited. The gain on sale of Rs 9,734 Lakhs has been recognized as an Exceptional Item in the Statement of Profit or Loss.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026 01-04-2026
Date of end of reporting period 30-06-2026 30-06-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026 01-04-2026
B Date of end of reporting period 30-06-2026 30-06-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit & loss (62.00) (62.00)
Total Amount of items that will not be reclassified to profit and loss (62.00)
2 Income tax relating to items that will not be reclassified to profit or loss (15.00) (15.00)
3 Amount of items that will be reclassified to profit and loss
1 Items that may be reclassified to profit or loss 118.00 118.00
Total Amount of items that will be reclassified to profit and loss 118.00
4 Income tax relating to items that will be reclassified to profit or loss 3.00 3.00
5 Total Other comprehensive income 68.00 68.00